Table 1.
Baseline Characteristics of the Included Studies
| Author | Disease/medication | Sample size | Age | Females, % | Minorities,% | Loss to follow-up% |
|---|---|---|---|---|---|---|
| Berger21 | Multiple sclerosis/Avonex | 212 | 45.6±9.1 | 83 | NR | 15.6 |
| Dilorio20 | HIV/HAART | 107 | 41 ± 6.9 | 34 | 94 | MI:25 CG:0 |
| Goggin25 20 | HIV/HAART | 70 | 41 ± 9.6 | 29 | 79 | MI:15 CG:21 |
| Golin22 | HIV/HAART | 68 | 39.9 ± 8.7 | 31 | 86 | MI:23 CG:25 |
| Holstad26 | HIV/HAART | 101 | 43.5 ± 9.1 | 100 | 94 | MI:12 CG:8 |
| Holstad16 | HIV/HAART | 28 | 31 ± 5.3 | 100 | 100 | MI:6.7 CG:33 |
| Ingersoll17 | HIV/HAART | 19 | 44 ± 5.1 | 63 | 94.8 | MI:25 CG:18 |
| Interian19 | Depression/antidepressants | 26 | 40.2 ± 10.8 | 73 | 100 | MI:12 CG:12 |
| Konkle-Parker15 | HIV/HAART | 33 | 34.9 ± 7.4 | 36 | 82 | MI:15 CG:17 |
| Lavoie18 | Asthma /ICS | 26 | 52 ± 15.0 | 50 | NR | MI:27 CG:21 |
| Ogedegbe29 | Hypertension/antihypertensives | 95 | 53.4 ± 11.3 | 50 | 100 | MI:3 CG:10 |
| Palacio27 | Cardiovascular/antiplatelet | 227 | 69.1 ± 8.6 | 44 | 100 | MI:6 CG:7 |
| Parsons24 | HIV/HAART | 65 | 43.6 ± 6.9 | 21 | 94 | MI:18 CG:13 |
| Pradier23 | HIVHAART | 123 | 40 [35–49] | 29 | NR | MI:<1 CG:<1 |
| Samet28 | HIV/HAART | 74 | 42.5 ± 7.9 | 22 | 66 | MI:4 CG:9 |
| Solomon32 | Osteoporosis | 1050 | 77.8 ± 6.4 | 94 | 10 | MI:9 CG:1.5 |
| Zwikker31 | Rheumatoid arthritis/DMD | 63 | 60.4 ± 12.1 | 67 | NR | MI:16 CG:2 |
NR: not reported
ICS: Inhaled corticosteroids
DMD: Disease-modifying drugs
MI: Motivational interviewing
CG: Control group